Enzo Biochem Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 2.03
Dividend & YieldN/A$ (N/A)
Beta 0.88
Market capitalization 55.05M
Operating cash flow -19.24M
ESG Scores unknown

Company description

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in Farmingdale, New York.

Sector: Healthcare - Industry: Diagnostics & Research

Financial data

Financial Statements

Cashflow Statement 2019-07-31 2020-07-31 2021-07-31 2022-07-31
Change To Liabilities -2.51M 1.21M -395k 390k
Total Cashflows From Investing Activities -8.13M -2.17M -34.5M 25.22M
Net Borrowings 4.1M 7M -339k -269k
Total Cash From Financing Activities 4.19M 7M -242k -241k
Change To Operating Activities -2.33M 5.04M 1.67M -3.19M
Issuance Of Stock 167k 97k 97k 28k
Net Income 2.49M -28.52M 7.88M -18.26M
Change In Cash 855k -12.28M -34.34M 8.33M
Effect Of Exchange Rate -18k 67k 11k -63k
Total Cash From Operating Activities 4.81M -17.18M 387k -16.59M
Depreciation 3.04M 2.78M 2.65M 2.83M
Change To Account Receivables 2.4M 1.62M -1.11M -1.3M
Other Cashflows From Financing Activities -70k
Change To Netincome 2.29M 604k -5.37M 5.68M
Capital Expenditures -8.13M -2.17M -4.44M -3.47M

Income Statement 2019-07-31 2020-07-31 2021-07-31 2022-07-31
Research Development 3.17M 4.45M 3.25M 3.77M
Income Before Tax 2.49M -28.52M 7.88M -18.26M
Net Income 2.49M -28.52M 7.88M -18.26M
Selling General Administrative 47.27M 49.69M 49.63M 53.31M
Gross Profit 23.25M 23.77M 53.58M 41.97M
Ebit -27.19M -30.37M 692k -15.11M
Operating Income -27.19M -30.37M 692k -15.11M
Interest Expense
Income Tax Expense
Total Revenue 81.17M 76.02M 117.73M 107.07M
Cost Of Revenue 57.92M 52.25M 64.15M 65.1M
Total Other Income ExpenseNet 29.68M 1.85M 7.18M -3.15M
Net Income From Continuing Ops 2.49M -28.52M 7.88M -18.26M
Net Income Applicable To Common Shares 2.49M -28.52M 7.88M -18.26M

Balance Sheet Statement 2019-07-31 2020-07-31 2021-07-31 2022-07-31
Total Liabilities 20.61M 54.16M 45.1M 41.4M
Total Stockholder Equity 86.03M 58.38M 68.59M 54.46M
Other Current Liabilities 2.53M 2.67M
Total Assets 106.64M 112.54M 113.69M 95.86M
Common Stock 476k 479k 485k 487k
Other Current Assets
Retained Earnings -249.73M -278.25M -270.38M -288.64M
Treasury Stock 2.58M 1.68M 1.35M 3.15M
Cash 60.15M 47.87M 13.52M 21.6M
Total Current Liabilities 16.01M 32.8M 26.08M 24.55M
Other Stockholder Equity 2.58M 1.68M 1.35M 3.15M
Property, Plant, and Equipment 14.25M 34.4M 33.6M 32.43M
Total Current Assets 81.45M 68.77M 70.58M 54.35M
Net Tangible Assets 77.54M 50.39M 60.89M 47.01M
Net Receivables 10.74M 9.14M 10.2M 11.52M
Accounts Payable 7.26M 8.5M 8.12M 8.51M


Insider Transactions

Here are the insider transactions of stock shares related to Enzo Biochem Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
WOLF JAMES GPurchase at price 1.28 - 1.29 per share.D/I2023-02-13Beneficial Owner of more than 10% of a Class of Security15k
WALTERS IAN B.Stock Award(Grant) at price 0.00 per share.D2023-02-13Director75.19k
TAGLIAFERRI MARY ANNStock Award(Grant) at price 0.00 per share.D2023-02-09Director75.19k
RADOFF BRADLEY LOUISStock Award(Grant) at price 0.00 per share.D2023-02-09Director75.19k
WOLF JAMES GPurchase at price 1.40 per share.D2023-01-27Beneficial Owner of more than 10% of a Class of Security11.8k
WOLF JAMES GConversion of Exercise of derivative security at price 2.50 - 5.00 per share.D2023-01-23Beneficial Owner of more than 10% of a Class of Security263.2k
CANNON KARAStock Award(Grant) at price 0.00 per share.D2022-12-28Chief Operating Officer12.6k
WOLF JAMES GConversion of Exercise of derivative security at price 2.50 per share.D2022-12-16Beneficial Owner of more than 10% of a Class of Security280k
ERFANIAN HAMIDPurchase at price 1.97 per share.D2022-11-23Chief Executive Officer100k
WOLF JAMES GPurchase at price 2.14 - 2.15 per share.I2022-11-01Beneficial Owner of more than 10% of a Class of Security23k
CANNON KARAPurchase at price 2.42 per share.D2022-07-15Chief Operating Officer2.5k
TAGLIAFERRI MARY ANNStock Award(Grant) at price 0.00 per share.D2022-07-12Director41.67k
RADOFF BRADLEY LOUISPurchase at price 2.27 per share.D2022-07-12Director12.5k
RADOFF BRADLEY LOUISStock Award(Grant) at price 0.00 per share.D2022-07-12Director41.67k
WALTERS IAN B.Stock Award(Grant) at price 0.00 per share.D2022-07-12Director41.67k
RADOFF BRADLEY LOUISPurchase at price 2.20 per share.D2022-07-05Director120k
RADOFF BRADLEY LOUISPurchase at price 2.20 - 2.21 per share.D2022-06-16Director125k
ERFANIAN HAMIDPurchase at price 2.19 per share.D2022-06-15Chief Executive Officer4.6k
BENCH DAVID A.Purchase at price 2.15 per share.I2022-06-14Chief Financial Officer3.5k
TAGLIAFERRI MARY ANNStock Award(Grant) at price 0.00 per share.D2022-04-27Director39.06k
RADOFF BRADLEY LOUISStock Award(Grant) at price 0.00 per share.D2022-04-27Director39.06k
WALTERS IAN B.Stock Award(Grant) at price 0.00 per share.D2022-04-27Director39.06k
RADOFF BRADLEY LOUISStock Award(Grant) at price 2.91 per share.I2022-04-14Director30k
BENCH DAVID A.Stock Award(Grant) at price 2.90 per share.I2022-04-14Chief Financial Officer2.5k
ERFANIAN HAMIDStock Award(Grant) at price 2.90 per share.D2022-04-13Chief Executive Officer10k
ERFANIAN HAMIDStock Award(Grant) at price 0.00 per share.D2021-11-08Chief Executive Officer260k
HARBERT MANAGEMENT CORPSale at price 2.96 - 4.70 per share.I2021-03-16Beneficial Owner of more than 10% of a Class of Security444.77k
RABBANI ELAZARStock Award(Grant) at price 0.00 per share.D2021-01-11Chief Executive Officer190.11k
WEINER BARRY WStock Award(Grant) at price 0.00 per share.D2021-01-11President142.59k
CLEMENS PETER J. IVPurchase at price 2.20 - 2.21 per share.D2020-02-18Beneficial Owner of more than 10% of a Class of Security10k
HARBERT MANAGEMENT CORPPurchase at price 3.06 - 3.11 per share.I2019-08-20Beneficial Owner of more than 10% of a Class of Security32.5k
HARBERT MANAGEMENT CORPPurchase at price 3.64 - 3.65 per share.I2019-07-23Beneficial Owner of more than 10% of a Class of Security418.84k
HARBERT MANAGEMENT CORPPurchase at price 3.06 - 3.10 per share.I2019-05-30Beneficial Owner of more than 10% of a Class of Security102.12k
HARBERT MANAGEMENT CORPPurchase at price 3.61 per share.I2019-05-20Beneficial Owner of more than 10% of a Class of Security14.13k
RABBANI ELAZARConversion of Exercise of derivative security at price 2.70 per share.D2019-01-14Chief Executive Officer2.78k
WEINER BARRY WConversion of Exercise of derivative security at price 2.70 per share.D2019-01-14President2.23k
PERLYSKY DOVConversion of Exercise of derivative security at price 2.70 per share.D2019-01-14Director9.18k
BORTZ GREGORY MConversion of Exercise of derivative security at price 2.70 per share.D2019-01-14Director9.18k
RABBANI ELAZARPurchase at price 3.35 per share.D2018-10-29Chief Executive Officer10k
PERLYSKY DOVPurchase at price 3.50 per share.D2018-10-18Director10k
HANNA BRUCE A. PH.D.Purchase at price 3.52 per share.D2018-10-18Director15k
RABBANI ELAZARSale at price 7.75 per share.D2018-01-17Chief Executive Officer14k
RABBANI ELAZARConversion of Exercise of derivative security at price 2.88 per share.D2018-01-17Chief Executive Officer38.51k
WEINER BARRY WSale at price 7.75 per share.D2018-01-17President11k
WEINER BARRY WConversion of Exercise of derivative security at price 2.88 per share.D2018-01-17President30.8k
PERLYSKY DOVSale at price 9.81 per share.D2017-10-31Director42k
PERLYSKY DOVConversion of Exercise of derivative security at price 2.88 per share.D2017-10-31Director59.45k
BORTZ GREGORY MSale at price 9.82 per share.D2017-10-31Director42.01k
BORTZ GREGORY MConversion of Exercise of derivative security at price 2.88 per share.D2017-10-31Director59.45k
O BRIEN JAMES MICHAELSale at price 10.28 per share.D2017-10-27Officer22.87k
O BRIEN JAMES MICHAELConversion of Exercise of derivative security at price 2.75 - 4.35 per share.D2017-10-27Officer22.87k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Enzo Biochem Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Enzo Biochem Inc

Here is the result of two systematic investment strategies applied to Enzo Biochem Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Enzo Biochem Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Enzo Biochem Inc:

Enzo Biochem Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 11.64% on the backtest period.

Performance at glance

Performance

11.64 %

Latent gain

261.69 $

Invested capital

2247.72 $

Annualized return

2.81 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Enzo Biochem Inc

This is the result of two momentum investment strategies applied to Enzo Biochem Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Enzo Biochem Inc

The following chart shows all the entries opened by the momentum investment system on Enzo Biochem Inc:

Enzo Biochem Inc momentum entries
  • The first momentum investment strategy would give 23.27% of return on Enzo Biochem Inc. That represents 1454.42$ of latent gain with 6249.72$ of employed capital.
  • The second momentum investment strategy would give 23.0% of return on Enzo Biochem Inc. That represents 747.93$ of latent gain with 3251.33$ of employed capital.
Performance at glance (1Q Momentum)

Performance

23.27 %

Latent gain

1454.42 $

Invested capital

6249.72 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

23.0 %

Latent gain

747.93 $

Invested capital

3251.33 $

Annualized return

6.28 %

Momentum equity curve on Enzo Biochem Inc

The following chart shows the equity curve of the two momentum strategies applied to Enzo Biochem Inc:

Enzo Biochem Inc momentum equity

Note: the dividends potentially given by Enzo Biochem Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Enzo Biochem Inc

The following chart shows the employed capital evolution of the two momentum strategies on Enzo Biochem Inc since the beginning:

Enzo Biochem Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Enzo Biochem Inc

Buy the dip entry openings on Enzo Biochem Inc

Enzo Biochem Inc

The performance achieved by the robo-advisor on Enzo Biochem Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Enzo Biochem Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Enzo Biochem Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Enzo Biochem Inc

The following chart shows the result of the investment strategy applied to Enzo Biochem Inc:

Enzo Biochem Inc

Note: the dividends potentially given by Enzo Biochem Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Enzo Biochem Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Enzo Biochem Inc:

Enzo Biochem Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Enzo Biochem Inc

In this section, I will compare the three previous investment strategies applied to Enzo Biochem Inc.

Equity curve comparison on Enzo Biochem Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Enzo Biochem Inc investment strategy comparison

Employed capital comparison on Enzo Biochem Inc

Enzo Biochem Inc investment comparison

Performance comparison on Enzo Biochem Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 11.64% 261.69$ 2247.72$ 2.81%
Momentum 1 quarter 23.27% 1454.42$ 6249.72$ 5.97%
Momentum 2 quarters 23.0% 747.93$ 3251.33$ 6.28%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

2.81 %

Momentum 1Q

6.28 %

Momentum 2Q

6.28 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Enzo Biochem Inc:

Positive correlations

Most correlated stocks this year

  • Enzo Biochem Inc

  • Most correlated stocks last 3 months

  • MOISELLE INTL
  • Enzo Biochem Inc

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • Keurig Dr Pepper Inc
  • AUSNUTRIA

  • Note: The algorithm computes the probability of correlation between Enzo Biochem Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Enzo Biochem Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Enzo Biochem Inc
    Country United States
    City Farmingdale
    Address 81 Executive Blvd.
    Phone 212 583 0100
    Website www.enzo.com
    FullTime employees 465
    Industry Diagnostics & Research
    Sector Healthcare
    Exchange XNYS
    Ticker ENZ
    Market www.nyse.com

    Enzo Biochem Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown